Abstract
Sequential monitoring in a clinical trial poses difficulty in hypotheses testing on secondary endpoints after the trial is terminated. The conventional likelihood-based testing procedure that ignores the sequential monitoring inflates Type I error and undermines power. In this article, we show that the power of the conventional testing procedure can be substantially improved while the Type I error is controlled. The method is illustrated with a real clinical trial.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Biometry / methods*
-
Child
-
Clinical Trials as Topic / methods*
-
Double-Blind Method
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Likelihood Functions
-
Models, Statistical
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Randomized Controlled Trials as Topic
-
Recombinant Proteins
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor